Idexx Laboratories (IDXX) share buybacks: $1.2B
Idexx Laboratories spent $1.2B buying back its own shares in the year ended Dec 31, 2025, up 45.4% from $837M a year earlier.
From Idexx Laboratories's filings with the SEC · Read the filing · IDXX stock page
Idexx Laboratories share buybacks by year
#172 of 1,890 US companies by share buybacks · See the full ranking
| Year ended | Share buybacks | Change |
|---|---|---|
| Dec 31, 2025 | $1.2B | +45% |
| Dec 31, 2024 | $837M | +1064% |
| Dec 31, 2023 | $71.9M | -91% |
| Dec 31, 2022 | $820M | +10% |
| Dec 31, 2021 | $747M | – |
Share buybacks of similar companies
Companies in the same industry as Idexx Laboratories, by SEC industry code, with the closest share buybacks. Each name opens the same page for that company.
| Company | Share buybacks, latest year | Year ended |
|---|---|---|
| Gilead Sciences | $1.9B | Dec 31, 2025 |
| Royalty Pharma | $1.2B | Dec 31, 2025 |
| Idexx Laboratories | $1.2B | Dec 31, 2025 |
| United Therapeutics | $1B | Dec 31, 2025 |
| AbbVie | $980M | Dec 31, 2025 |
| Exelixis | $948M | Jan 2, 2026 |
| Abbott Laboratories | $893M | Dec 31, 2025 |
Questions and answers
What is Idexx Laboratories's share buybacks?
Idexx Laboratories spent $1.2B buying back its own shares in the year ended Dec 31, 2025, up 45.4% from $837M a year earlier.
Numbers as reported in Idexx Laboratories's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology